NURS-6521 Week 6: Neurologic and Musculoskeletal Disorders Papers

Sabrina is a 26 year old female who has just been diagnosed with multiple sclerosis. She has scheduled an appointment for a follow up with her physician but has several questions about her diagnosis and is calling the Nurse Helpline for her hospital network. As she talks with the advanced practice nurse, she learns that her diagnosis also impacts her neurologic and musculoskeletal systems. Although multiple sclerosis is an autoimmune disorder, both the neurologic and musculoskeletal systems will be affected by adverse symptoms that Sabrina needs to be aware of and for which specific drug therapy plans and other treatment options need to be decided on. 

As an advanced practice nurse, what types of drugs will best address potential neurologic and musculoskeletal symptoms Sabrina might experience?

This week, you will evaluate patients for the treatment of neurologic and musculoskeletal disorders by focusing on specific patient case studies through a decision tree exercise. You will analyze the decisions you will make in the decision tree exercise and reflect on your experiences in proposing the recommended actions to address the health needs in the patient case study.

Learning Objectives

Students will:

• Evaluate patients for treatment of neurologic and musculoskeletal disorders
• Analyze decisions made throughout the diagnosis and treatment of patients with neurologic and musculoskeletal disorders
• Justify decisions made throughout the diagnosis and treatment of patients with neurologic and musculoskeletal disorders

NURS-6521 Week 6: Neurologic and Musculoskeletal Disorders Papers Learning Resources

Required Readings (click to expand/reduce)

Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.

• Chapter 10, “Basic Principles of Neuropharmacology” (pp. 73–77)
• Chapter 11, “Physiology of the Peripheral Nervous System” (pp. 79–90)
• Chapter 12, “Muscarinic Agonists and Antagonists” (pp. 91–107)
• Chapter 13, “Adrenergic Agonists” (pp. 109–119)
• Chapter 14, “Adrenergic Antagonists” (pp. 121–132)
• Chapter 15, “Indirect-Acting Antiadrenergic Agents” (pp. 133–137)
• Chapter 16, “Introduction to Nervous System Pharmacology” (pp. 139–141)
• Chapter 17, “Drugs for Parkinson Disease” (pp. 143–158)
• Chapter 18, “Drugs for Alzheimer Disease” (pp. 159–166)
• Chapter 19, “Drugs for Epilepsy” (pp. 167–189)
• Chapter 20, “Drugs for Muscle Spasm and Spasticity” (pp. 191–201)
• Chapter 57, “Drug Therapy of Rheumatoid Arthritis” (pp. 629–641)
• Chapter 58, “Drug Therapy of Gout” (pp. 643–651)
• Chapter 59, “Drugs Affecting Calcium Levels and Bone Mineralization” (pp. 653–672)

American Academy of Family Physicians. (2019). Dementia. Retrieved from http://www.aafp.org/afp/topicModules/viewTopicModule.htm?topicModuleId=5

This website provides information relating to the diagnosis, treatment, and patient education of dementia. It also presents information on complications and special cases of dementia.

Document: Mid-Term Summary & Study Guide (PDF)

Required Media (click to expand/reduce)

Laureate Education (Producer). (2019b). Alzheimer’s disease [Interactive media file]. Baltimore, MD: Author.

In this interactive media piece, you will engage in a set of decisions for prescribing and recommending pharmacotherapeutics to treat Alzheimer’s disease.

Laureate Education (Producer). (2019e). Complex regional pain disorder [Interactive media file]. Baltimore, MD: Author.

In this interactive media piece, you will engage in a set of decisions for prescribing and recommending pharmacotherapeutics to treat complex regional pain disorders.

Disorders of The Nervous System

Reflect on the comprehensive review of disorders of the nervous system and think about how you might recommend or prescribe pharmacotherapeutics to treat these disorders. (15m)

Assignment: Decision Tree for Neurological and Musculoskeletal Disorders